FDA Approves Emergency Use Authorization For Gilead’s Remdesivir To Treat Patients With COVID-19; BARDA Researching New Diagnostic Test

STAT: FDA to allow emergency use of Gilead’s Covid-19 drug
“The Food and Drug Administration announced Friday that it would permit emergency use of remdesivir, the antiviral medicine from Gilead Sciences, to treat patients with Covid-19. The decision to issue an ’emergency use authorization’ was based on positive results from a government-conducted clinical trial, announced Wednesday, that showed remdesivir accelerated the recovery time of patients with Covid-19 compared to a placebo and from a study conducted by Gilead that studied two different treatment durations of the medicine…” (Feuerstein/Herper, 5/1).

The Guardian: U.S. germ warfare research leads to new early Covid-19 test (Tremlett, 5/1).

New York Times: How Remdesivir, New Hope for Covid-19 Patients, Was Resurrected (Kolata, 5/1).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.